Sugi Predict

Sugi Predict / Targets / CYP46A1

CYP46A1

Cholesterol 24-hydroxylase · Q9Y6A2 · CYP46A1 on Sugi Atlas →

34,652 patent compounds predicted against CYP46A1, 25,933 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Efavirenz Efavirenz (SCHEMBL37762) 1.00 10/20
Efavirenz Efavirenz (SCHEMBL464769) 1.00 10/20
Efavirenz Efavirenz (SCHEMBL297896) 0.53 9/20
SCHEMBL615742 SCHEMBL615742 0.53 7/20
SCHEMBL613242 SCHEMBL613242 0.52 7/20
Delavirdine Delavirdine (SCHEMBL328863) 0.45 7/20
SCHEMBL614342 SCHEMBL614342 0.53 5/20
SCHEMBL612478 SCHEMBL612478 0.46 5/20
SCHEMBL524307 SCHEMBL524307 0.36 5/20
SCHEMBL524308 SCHEMBL524308 0.36 5/20
SCHEMBL613316 SCHEMBL613316 0.34 5/20
SCHEMBL158246 SCHEMBL158246 1.00 3/20
SCHEMBL161397 SCHEMBL161397 1.00 3/20
SCHEMBL192029 SCHEMBL192029 1.00 3/20
Marein Marein (SCHEMBL620953) 0.53 3/20
Marein Marein (SCHEMBL620954) 0.53 3/20
SCHEMBL156472 SCHEMBL156472 0.49 3/20
SCHEMBL612014 SCHEMBL612014 0.38 3/20
Cholesterol Cholesterol (SCHEMBL192030) 0.91 2/20
Cholesterol Cholesterol (SCHEMBL159924) 0.89 2/20

Clinical trials — most relevant to CYP46A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Silymarin in Rheumatoid Arthritis Patients Treated With Methotrexate PHASE4NOT_YET_RECRUITING
LDL Receptor Under Ezetimibe and Simvastatin PHASE4COMPLETED
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity PHASE4COMPLETED
Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy PHASE3COMPLETED
Smith-Lemli-Opitz Syndrome and Cholic Acid PHASE1/PHASE2COMPLETED
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis PHASE2COMPLETED
Androgen Reduction in Congenital Adrenal Hyperplasia PHASE2WITHDRAWN
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome PHASE2COMPLETED
Efavirenz for Patients With Alzheimer's Disease PHASE1COMPLETED
The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH PHASE1UNKNOWN
Effect of Bariatric Surgery on Bile Acid Homeostasis nanCOMPLETED
Regulation of Sterol Homeostasis nanCOMPLETED
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum nanCOMPLETED
Normal Pressure Hydrocephalus Biomarkers Investigation nanUNKNOWN
Cholesterol Metabolites as Markers for CYP3A Induction nanCOMPLETED
The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus nanCOMPLETED
Study of Smith-Lemli-Opitz Syndrome nanCOMPLETED
Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health nanUNKNOWN
Mutation Analysis of 17α-Hydroxylase nanUNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes nanNOT_YET_RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Replacement of Vitamin D in Patients With Active Tuberculosis nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism nanRECRUITING
Influence of Polyglucosamine L112 on Serum Surrogate Markers of Cholesterol Absorption nanCOMPLETED
Cholestanol in Humans nanWITHDRAWN
Cholesterol Homeostasis in Framingham Offspring Study nanCOMPLETED
Exome Sequencing in Autistic Spectrum Disorder nanCOMPLETED
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP46A1 binder may also engage these)

ProteinNameSimilarity
Q9WVK8 — 1.000 Q9WVK8 →
P14581 — 0.986 P14581 →
P14579 — 0.983 P14579 →
Q9GJX5 — 0.983 Q9GJX5 →
Q8SPK0 — 0.982 Q8SPK0 →
CYP4A11 Cytochrome P450 4A11 0.979 landscape →
O77809 — 0.978 O77809 →
P14580 — 0.977 P14580 →
P10611 — 0.977 P10611 →
Q8SPK1 — 0.976 Q8SPK1 →
Q5KQT6 — 0.974 Q5KQT6 →
CYP1A2 Cytochrome P450 1A2 0.973 landscape →
P15539 — 0.969 P15539 →
Q64658 — 0.969 Q64658 →
P97720 — 0.969 P97720 →
Q4H4C3 — 0.968 Q4H4C3 →
P30099 — 0.968 P30099 →
P00187 — 0.968 P00187 →
O77810 — 0.967 O77810 →
P30100 — 0.967 P30100 →
P17178 — 0.966 P17178 →
P00185 — 0.965 P00185 →
Q5RBQ1 — 0.965 Q5RBQ1 →
Q3LFT9 — 0.965 Q3LFT9 →
O35728 — 0.965 O35728 →
CYP4A22 Cytochrome P450 4A22 (CYPIVA22) (Fatty acid o 0.965 landscape →
P20817 — 0.965 P20817 →
P56590 — 0.964 P56590 →
Q3LFU0 — 0.963 Q3LFU0 →
CYP4B1 Cytochrome P450 4B1 (EC 1.14.14.1) (CYPIVB1) 0.963 landscape →